
Friday, January 10, 2025 10:51:14 AM
07:30:00 AM ET, 01/10/2025 - GlobeNewswire
VANCOUVER, Wash. and PARIS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, and Owkin, a TechBio that uses agentic AI to unlock complex targets for drug discovery, development, and diagnostics, today announced a partnership bringing together two leading AI platforms to rapidly discover and design novel therapeutics for patients.
“At Absci, we’re constantly pushing the boundaries of innovation to bring better biologics to patients faster,” said Sean McClain, Founder and CEO of Absci. “By combining Absci’s AI de novo design expertise with Owkin’s world-class predictive AI target discovery technology, we have a unique opportunity to design first-in-class and potentially transformative therapeutics for patients in need.”
Through this strategic partnership, Absci and Owkin will co-develop therapeutic candidates addressing novel targets in immuno-oncology and other indications, such as immunology and inflammation. Owkin’s predictive AI models will optimize target selection and validate therapeutic hypotheses using extensive biomedical datasets and patient-derived organoids. Absci’s generative AI Drug Creation platform, including its de novo antibody design models, will rapidly design therapeutic candidates against these novel targets. Together, the companies will aim to streamline and accelerate the path from research to clinical development.
“At Owkin, our mission is to use patient data and Owkin K, our Operating System, to revolutionize drug discovery and development,” said Thomas Clozel, MD, CEO and Co-Founder of Owkin. “This partnership with Absci represents a significant step forward in our journey to bring transformative therapies to patients. By bringing together Owkin’s AI agents that can identify and experimentally validate novel therapeutic targets with Absci’s pioneering capabilities in developing biologic drug candidates, we aim to accelerate the delivery of next-generation treatments.”
This collaboration builds on Absci’s growing portfolio of partnerships with industry leaders such as AstraZeneca and Merck, as well as its robust internal pipeline of drug candidates. With this new partnership, Absci has added drug creation partnerships with four new Partners in 2024, achieving the Company's outlook for the year. Similarly, Owkin has established itself as a pioneer in predictive AI, working with top-tier pharmaceutical companies such as Sanofi and BMS to advance drug discovery and development as well as its differentiated pipeline of drug candidates and AI diagnostics
Volume: | 4,595,400 |
Day Range: | 5.05 - 5.54 |
Bid: | 5.17 |
Ask: | 5.18 |
Last Trade Time: | 4:41:22 PM EST |
Total Trades: | 30,663 |
Recent ABSI News
- Absci to Participate in the TD Cowen 45th Annual Health Care Conference • GlobeNewswire Inc. • 02/18/2025 01:00:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/14/2025 04:23:34 PM
- FDA Approval Race: AI-Powered Innovations Reshape the Healthcare Landscape • PR Newswire (US) • 02/11/2025 02:00:00 PM
- FDA Approval Race: AI-Powered Innovations Reshape the Healthcare Landscape • PR Newswire (Canada) • 02/11/2025 02:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2025 09:31:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2025 09:31:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2025 09:31:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2025 09:30:28 PM
- Small Cap Finds Mid-Week Success On Dual Announcement • AllPennyStocks.com • 01/22/2025 09:45:00 PM
- Absci to Participate in the Guggenheim Securities SMID Cap Biotech Conference • GlobeNewswire Inc. • 01/22/2025 01:00:00 PM
- Healthcare AI Adoption Accelerates as Industry Eyes $125 Billion Growth by 2028 • PR Newswire (US) • 01/17/2025 10:58:00 PM
- Healthcare AI Adoption Accelerates as Industry Eyes $125 Billion Growth by 2028 • PR Newswire (Canada) • 01/17/2025 10:56:00 PM
- Healthcare AI Adoption Accelerates as Industry Eyes $125 Billion Growth by 2028 • PR Newswire (US) • 01/17/2025 10:56:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2025 09:31:15 PM
- Absci and Owkin Synergize Leading TechBio Platforms to Advance Generative AI Drug Discovery • GlobeNewswire Inc. • 01/10/2025 12:30:00 PM
- Absci and AMD Announce Collaboration and Strategic Investment to Accelerate the Future of AI Drug Discovery • GlobeNewswire Inc. • 01/08/2025 12:00:00 PM
- Absci and Invetx Partner to Bring Generative AI Drug Creation Platform to Animal Health • GlobeNewswire Inc. • 01/06/2025 01:00:00 PM
- Absci to Participate in the 43rd Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/02/2025 01:00:00 PM
- Absci Highlights Progress and Updates Across Proprietary Pipeline and Leading AI Platform at 2024 R&D Day • GlobeNewswire Inc. • 12/12/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/09/2024 09:07:05 PM
- Wall Street Analysts Were Busy This Morning • AllPennyStocks.com • 12/04/2024 01:45:00 PM
- Absci to Participate in the 36th Annual Piper Sandler Healthcare Conference • GlobeNewswire Inc. • 11/21/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2024 12:31:59 PM
Consumer Automotive Finance Inc. (CAFI) Completes Final Steps with FINRA, Expects Name and Ticker Change to Fifty 1 Labs, Inc. (FITY) Within 30 Days • CAFI • Feb 20, 2025 9:00 AM
UAV Corp Unveils AIG's Arrival and Cutting-Edge 3D Printing Technology, Paving the Way for Full-Scale T-Wing UAS Production and the Future of Aerospace and Defense Manufacturing • UMAV • Feb 20, 2025 8:30 AM
North Bay Resources Announces Production of 8.5 Ounces Per Ton Gold Concentrate, Bishop Gold Mill, California • NBRI • Feb 19, 2025 8:59 AM
YCRM ReachOut Technology Returns to Trading: CEO Rick Jordan Lays Out Blockchain CyberSecurity Strategy and Industry-First AI MSP Partnership In Shareholder Letter • YCRM • Feb 18, 2025 11:20 AM
VAYK Confirms No Dilution Following Recent Acquisition and 11 Million Insider Purchase • VAYK • Feb 18, 2025 9:30 AM
UAV Corp. (OTC: UMAV) Announces Nationwide Teleconference to Provide Shareholders with Key Updates on Contracts, Future Plans, and Share Structure • UMAV • Feb 18, 2025 8:30 AM